Scientific Sessions 2024  /  Featured Science: Novel Approaches to Managing Lipid Risk  /  Discussant: YELLOW III
Logo

American Heart Association

  7
  0

Final ID:

Discussant: YELLOW III

  • Mora, Samia  ( BRIGHAM AND WOMENS HOSPITAL , Boston , Massachusetts , United States )
  • Kramer, Christopher  ( Univ. of Virginia Health System , Charlottesville , Virginia , United States )
    • Author Disclosures:
    Samia Mora: DO have relevant financial relationships ; Royalties/Patent Beneficiary:co-inventor on patent application on glycosylation and cardiovascular disease issued to Genos and Brigham and Women's Hospital:Active (exists now) | Christopher Kramer: DO have relevant financial relationships ; Research Funding (PI or named investigator):BMS:Active (exists now) ; Research Funding (PI or named investigator):Cytokinetics:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Featured Science: Novel Approaches to Managing Lipid Risk

Saturday, 11/16/2024 , 01:30PM - 02:45PM

Featured Science

More abstracts on this topic:
Long-term Efficacy of Lerodalcibep in 1,468 Patients at Very High and High Risk for CVD in the 72 week Open-Label Extension Trial

Kereiakes Dean, Fourie Nyda, Scott Russell, Asprusten Emil, Yalim Zafer, Vest Jeff, Kallend David, Stein Evan

Novel Lipid Targets and Vascular Outcomes

Libby Peter, Ginsberg Henry

More abstracts from these authors:
Effect of Tirzepatide on Cardiac Structure and Function in Obese HFpEF: the SUMMIT CMR Substudy

Kramer Christopher

What a New CV Board Might Mean for Me?

Kramer Christopher, Fry Edward

You have to be authorized to contact abstract author. Please, Login
Not Available